RecruitingPhase 2NCT01297400

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

Sponsor

Skingenix, Inc.

Enrollment

60 participants

Start Date

Mar 11, 2022

Study Type

INTERVENTIONAL

Conditions

Burns

Summary

To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Adults, 18 years of age or older on the day of signing the informed consent.
Thermal Burns not exceeding a total body surface area (TBSA) OF 25%, with at least one partial thickness burn of 0.5% TBSA or greater. If full thickness burn(s) are present at screening, the total full thickness burn area shall not exceed 10% TBSA. Note: TBSA excludes areas of superficial (first degree) burns.
Able and willing to give informed consent and comply with study procedures.

Exclusion Criteria5

Any burn that at screening is:
infected.
circumferential or deemed, in the judgment of the investigator, at high risk for developing compartment syndrome.
partial thickness that is likely, in the judgment of the Investigator, to require grafting within 72 hours, or other non-protocol intervention.
Severe inhalation injury or other significant non-burn trauma.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.